Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing to take part voluntarily and agree to follow the study requirements by signing a consent form.
• People aged 18 or older, of any gender.
• People who are generally well enough to carry out daily activities with little or no limitation (based on a standard health performance scale scored 0 or 1).
• People who have been confirmed by tissue testing to have a specific type of esophageal cancer (squamous cell carcinoma) that has not spread to distant parts of the body, and whose cancer is considered removable by surgery, at certain defined stages.
• People who have not previously received any treatment for esophageal cancer, including chemotherapy, hormone therapy, radiation, or immunotherapy.
• People whose recent blood test results (taken within 7 days before joining) show that blood cell counts, liver function, kidney function, blood clotting, thyroid hormone levels, and heart pumping function all fall within the ranges required by the trial.
• Women who agree to use effective contraception during the study and for 6 months after it ends, have a negative pregnancy test within 7 days before joining, and are not breastfeeding.
• Men who agree to use effective contraception during the study and for 6 months after it ends.
• People who carry certain markers for hepatitis B (HBsAg or HBcAb positive) may still be considered if their hepatitis B virus levels are low enough and they are receiving or will begin appropriate antiviral treatment (confirm with trial site).

Who may not be able to join:

• People who have another type of cancer, except for a previously cured form of skin cancer called basal cell carcinoma.
• People whose esophageal cancer is located in the cervical (neck) portion of the esophagus.
• People who have had a severe allergic reaction to another monoclonal antibody treatment in the past.
• People who have an active autoimmune disease or a history of one — such as autoimmune liver disease, lung inflammation, bowel inflammation, blood vessel inflammation, kidney inflammation, or asthma needing certain medications — though some milder conditions may be acceptable (confirm with trial site).
• People who are currently taking immunosuppressant medications or steroid medications at doses above a certain level, and have continued taking them within 2 weeks before the first study dose.
• People who have fluid build-up around the lungs, heart, or abdomen that is uncontrolled and requires repeated draining.
• People who have uncontrolled symptoms from cancer that has spread to the brain or spine, or evidence of such spread found on a scan, within 4 weeks before the first study dose.
• People with serious uncontrolled heart conditions, such as a recent or ongoing lack of blood flow to the heart, a heart attack, a significant irregular heartbeat, moderate to severe heart failure, or reduced heart pumping function below a certain level.
• People with a serious active or uncontrolled infection of a certain severity.
• People who have received a live or preventive vaccine within 4 weeks before the first study dose.
• People who have other serious illnesses — including mental health conditions — significant abnormal test results, or personal or social circumstances that the study doctor believes could make participation unsafe or lead to early withdrawal.
• People who test positive for hepatitis C virus and have virus levels above a certain amount in their blood.
• People who test positive for HIV.

Important: Always verify eligibility with the trial site directly before applying.